Generation and Initial Characterization of FDD Knock in Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2009 Nov 20

PMID 19924302

Citations 26

Authors

Luca Giliberto

Shuji Matsuda

Ruben Vidal

Luciano DAdamio

Affiliations

Soon will be listed here.

Abstract

Background: Mutations in the integral membrane protein 2B, also known as BRI(2), a type II trans-membrane domain protein cause two autosomal dominant neurodegenerative diseases, Familial British and Danish Dementia. In these conditions, accumulation of a C-terminal peptide (ABri and ADan) cleaved off from the mutated precursor protein by the pro-protein convertase furin, leads to amyloid deposition in the walls of blood vessels and parenchyma of the brain. Recent advances in the understanding of the generation of amyloid in Alzheimer's disease has lead to the finding that BRI(2) interacts with the Amyloid Precursor Protein (APP), decreasing the efficiency of APP processing to generate Abeta. The interaction between the two precursors, APP and BRI(2), and possibly between Abeta and ABri or ADan, could be important in influencing the rate of amyloid production or the tendency of these peptides to aggregate.

Methodology/principal Findings: We have generated the first BRI(2) Danish Knock-In (FDD(KI)) murine model of FDD, expressing the pathogenic decamer duplication in exon 6 of the BRI(2) gene. FDD(KI) mice do not show any evident abnormal phenotype, with normal brain histology and no detectable amyloid deposition in blood vessel walls or parenchyma.

Conclusions/significance: This new murine mouse model will be important to further understand the interaction between APP and BRI(2), and to provide insights into the molecular basis of FDD.

Citing Articles

Initial assessment of the spatial learning, reversal, and sequencing task capabilities of knock-in rats with humanizing mutations in the Aβ-coding region of App.

Pham H, Yin T, DAdamio L PLoS One. 2022; 17(5):e0263546.

PMID: 35507596 PMC: 9067689. DOI: 10.1371/journal.pone.0263546.

Danish and British dementia ITM2b/BRI2 mutations reduce BRI2 protein stability and impair glutamatergic synaptic transmission.

Yin T, Yao W, Lemenze A, DAdamio L J Biol Chem. 2020; 296:100054.

PMID: 33172889 PMC: 7948410. DOI: 10.1074/jbc.RA120.015679.

Facilitation of glutamate, but not GABA, release in Familial Alzheimer's APP mutant Knock-in rats with increased β-cleavage of APP.

Tambini M, Yao W, DAdamio L Aging Cell. 2019; 18(6):e13033.

PMID: 31496118 PMC: 6826143. DOI: 10.1111/acel.13033.

Tuning of Glutamate, But Not GABA, Release by an Intrasynaptic Vesicle APP Domain Whose Function Can Be Modulated by β- or α-Secretase Cleavage.

Yao W, Tambini M, Liu X, DAdamio L J Neurosci. 2019; 39(35):6992-7005.

PMID: 31235642 PMC: 6733572. DOI: 10.1523/JNEUROSCI.0207-19.2019.

BRI2 as an anti-Alzheimer gene.

Matsuda S, Senda T Med Mol Morphol. 2018; 52(1):1-7.

PMID: 29687167 DOI: 10.1007/s00795-018-0191-1.

References

Deleersnijder W, Hong G, Cortvrindt R, Poirier C, Tylzanowski P, Pittois K . Isolation of markers for chondro-osteogenic differentiation using cDNA library subtraction. Molecular cloning and characterization of a gene belonging to a novel multigene family of integral membrane proteins. J Biol Chem. 1996; 271(32):19475-82. DOI: 10.1074/jbc.271.32.19475. View

Matsuda S, Giliberto L, Matsuda Y, McGowan E, DAdamio L . BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate. J Neurosci. 2008; 28(35):8668-76. PMC: 3844774. DOI: 10.1523/JNEUROSCI.2094-08.2008. View

Wakayama T, Rodriguez I, Perry A, Yanagimachi R, Mombaerts P . Mice cloned from embryonic stem cells. Proc Natl Acad Sci U S A. 1999; 96(26):14984-9. PMC: 24759. DOI: 10.1073/pnas.96.26.14984. View

Vidal R, Revesz T, Rostagno A, Kim E, Holton J, Bek T . A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A. 2000; 97(9):4920-5. PMC: 18333. DOI: 10.1073/pnas.080076097. View

Akiyama H, Kondo H, Arai T, Ikeda K, Kato M, Iseki E . Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol. 2003; 107(1):53-8. DOI: 10.1007/s00401-003-0783-1. View

Pittois K, Wauters J, Bossuyt P, Deleersnijder W, Merregaert J . Genomic organization and chromosomal localization of the Itm2a gene. Mamm Genome. 1999; 10(1):54-6. DOI: 10.1007/s003359900942. View

McGowan E, Eriksen J, Hutton M . A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet. 2006; 22(5):281-9. DOI: 10.1016/j.tig.2006.03.007. View

Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J . Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem. 2006; 96(3):732-42. DOI: 10.1111/j.1471-4159.2005.03578.x. View

Plant G, Revesz T, BARNARD R, Harding A, GAUTIER-SMITH P . Familial cerebral amyloid angiopathy with nonneuritic amyloid plaque formation. Brain. 1990; 113 ( Pt 3):721-47. DOI: 10.1093/brain/113.3.721. View

10.

De Strooper B . Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007; 8(2):141-6. PMC: 1796779. DOI: 10.1038/sj.embor.7400897. View

11.

Matsuda S, Matsuda Y, Snapp E, DAdamio L . Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. Neurobiol Aging. 2009; 32(8):1400-8. PMC: 2932834. DOI: 10.1016/j.neurobiolaging.2009.08.005. View

12.

Matsuda S, Matsuda Y, DAdamio L . BRI3 inhibits amyloid precursor protein processing in a mechanistically distinct manner from its homologue dementia gene BRI2. J Biol Chem. 2009; 284(23):15815-25. PMC: 2708878. DOI: 10.1074/jbc.M109.006403. View

13.

Sanchez-Pulido L, Devos D, Valencia A . BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem Sci. 2002; 27(7):329-32. DOI: 10.1016/s0968-0004(02)02134-5. View

14.

Holton J, Ghiso J, Lashley T, Rostagno A, GuErin C, Gibb G . Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia. Am J Pathol. 2001; 158(2):515-26. PMC: 1850296. DOI: 10.1016/S0002-9440(10)63993-4. View

15.

Kim S, Wang R, Gordon D, Bass J, Steiner D, Lynn D . Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nat Neurosci. 1999; 2(11):984-8. DOI: 10.1038/14783. View

16.

Shen J, Kelleher 3rd R . The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A. 2007; 104(2):403-9. PMC: 1766397. DOI: 10.1073/pnas.0608332104. View

17.

Tomidokoro Y, Lashley T, Rostagno A, Neubert T, Bojsen-Moller M, Braendgaard H . Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. J Biol Chem. 2005; 280(44):36883-94. DOI: 10.1074/jbc.M504038200. View

18.

Saura C, Choi S, Beglopoulos V, Malkani S, Zhang D, Rao B . Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004; 42(1):23-36. DOI: 10.1016/s0896-6273(04)00182-5. View

19.

Giliberto L, Zhou D, Weldon R, Tamagno E, De Luca P, Tabaton M . Evidence that the Amyloid beta Precursor Protein-intracellular domain lowers the stress threshold of neurons and has a "regulated" transcriptional role. Mol Neurodegener. 2008; 3:12. PMC: 2538519. DOI: 10.1186/1750-1326-3-12. View

20.

Rostagno A, Revesz T, Lashley T, Tomidokoro Y, Magnotti L, Braendgaard H . Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J Biol Chem. 2002; 277(51):49782-90. DOI: 10.1074/jbc.M206448200. View